Plus, the secret’s out on the Catskills, and Democrats gear up for a wave of investigations into Trump and his allies.

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the ...

The announcement by Moderna Inc. and Merck & Co. that a messenger RNA-based cancer vaccine had lowered the recurrence rate ...

The companies said their vaccine helped prevent the return and spread of melanoma in a trial that involved more than 1,000 ...

ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer ...

It was given to patients with high-risk melanoma - the most aggressive form of skin cancer causing about 2,600 deaths a year ...

Moderna shares surged more than 170 percent in a single session after a personalized messenger RNA cancer vaccine ...

The messenger RNA (mRNA) technology that became humanity's frontline defense during the COVID-19 pandemic has now crossed a ...

Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine.

Pharmaceutical group Moderna has reported "top-line" results from their cancer vaccine, especially for malanoma.

Health-care companies rose as traders rotated into high-risk areas such as biotechnology. Moderna shares rose 9% as a breakthrough in skin-cancer vaccines, divulged earlier this week, continued to ...

Firstpost brings out an expert’s view on the growing link between obesity and cancer, how excess body fat may increase cancer ...